Bibliography

Research using CPRD data has informed drug safety guidance and clinical practice and resulted in over 2,700 peer-reviewed publications. The CPRD bibliography is updated on a monthly basis (last updated 4 March 2021) and papers are listed below and in the PDF below.

If you have published papers using CPRD data which are not included in this list, please contact us at enquiries@cprd.com so that we can update the bibliography.

Download:

 (PDF, 3MB, 220 pages) 

This work uses data provided by patients and collected by the NHS as part of their care and support. CPRD encourages researchers to use this citation in all publications using CPRD data. Find out more about acknowledging the use of patient data at the Understanding Patient Data website. 

 

 

Export 2741 results:
Author Title [ Type(Asc)] Year
Journal Article
A. Jain, Walker, J. L., Mathur, R., Forbes, H. J., Langan, S. M., Smeeth, L., van Hoek, A. J., and Thomas, S. L., “Zoster vaccination inequalities: A population based cohort study using linked data from the UK Clinical Practice Research Datalink”, PLoS One, vol. 13, p. e0207183, 2018.
J. Erwin, Enki, D. G., and Woolf, A. D., “Younger people with rheumatoid arthritis are at increased risk of fracture even before age 50 years: a population-based cohort study”, Osteoporos Int, 2021.
C. Gilbert, Allgar, V., and Doran, T., “Workload impact of the Quality and Outcomes Framework for patients with diabetes: an interrupted time series in general practice”, Br J Gen Pract, vol. 69, pp. e570-e577, 2019.
E. Kontopantelis, Springate, D., Reeves, D., Ashcroft, D. M., Valderas, J. M., and Doran, T., “Withdrawing performance indicators: retrospective analysis of general practice performance under UK Quality and Outcomes Framework”, Bmj, vol. 348, p. g330, 2014.
M. Ashworth, Latinovic, R., Charlton, J., Cox, K., Rowlands, G., and Gulliford, M., “Why has antibiotic prescribing for respiratory illness declined in primary care? A longitudinal study using the General Practice Research Database”, J Public Health (Oxf), vol. 26, pp. 268-74, 2004.
J. N. Bashford, Norwood, J., and Chapman, S. R., “Why are patients prescribed proton pump inhibitors? Retrospective analysis of link between morbidity and prescribing in the General Practice Research Database”, Bmj, vol. 317, pp. 452-6, 1998.
C. C. Yang, Jick, S. S., and Testa, M. A., “Who receives lipid-lowering drugs: the effects of comorbidities and patient characteristics on treatment initiation”, Br J Clin Pharmacol, vol. 55, pp. 288-98, 2003.
J. C. Robson, Kiran, A., Maskell, J., Hutchings, A., Arden, N., Dasgupta, B., Hamilton, W., Emin, A., Culliford, D., and Luqmani, R., “Which Patients with Giant Cell Arteritis Will Develop Cardiovascular or Cerebrovascular Disease? A Clinical Practice Research Datalink Study”, J Rheumatol, vol. 43, pp. 1085-92, 2016.
T. P. Chu, Shah, A., Walker, D., and Coleman, M. P., “Where are the opportunities for an earlier diagnosis of primary intracranial tumours in children and young adults?”, Eur J Paediatr Neurol, vol. 21, pp. 388-395, 2017.
A. J. Walker, West, J., Card, T. R., Crooks, C., Kirwan, C. C., and Grainge, M. J., “When are breast cancer patients at highest risk of venous thromboembolism? A cohort study using English health care data”, Blood, vol. 127, pp. 849-57; quiz 953, 2016.
P. A. Tiffin, Mediavilla, J. L., Close, H., Kasim, A. S., Welsh, P., Paton, L. W., and Mason, J. M., “What were the impacts of the Committee on Safety of Medicines warning and publication of the NICE guidelines on trends in child and adolescent antidepressant prescribing in primary care? A population based study”, BMJ Open, vol. 9, p. e028201, 2019.
A. P. McGovern, Dennis, J. M., Shields, B. M., Hattersley, A. T., Pearson, E. R., and Jones, A. G., “What to do with diabetes therapies when HbA1c lowering is inadequate: add, switch, or continue? A MASTERMIND study”, BMC Med, vol. 17, p. 79, 2019.
W. D. Strain, Tsang, C., Hurst, M., McEwan, P., Unadkat, M., Meadowcroft, S., Shardlow, R., and Evans, M., “What Next After Metformin in Type 2 Diabetes? Selecting the Right Drug for the Right Patient”, Diabetes Ther, vol. 11, pp. 1381-1395, 2020.
C. L. Morgan, Poole, C. D., Evans, M., Barnett, A. H., Jenkins-Jones, S., and Currie, C. J., “What next after metformin? A retrospective evaluation of the outcome of second-line, glucose-lowering therapies in people with type 2 diabetes”, J Clin Endocrinol Metab, vol. 97, pp. 4605-12, 2012.
S. Mukherjee, Culliford, D., Arden, N., and Edwards, C., “What is the risk of having a total hip or knee replacement for patients with lupus?”, Lupus, vol. 24, pp. 198-202, 2015.
J. S. Minhas, Coles, B., Mistri, A. K., Eveson, D. J., Hussain, S. T., Potter, J. F., Khunti, K., and Robinson, T. G., “What is the optimal blood pressure level for patients with atrial fibrillation treated with direct oral anticoagulants?”, J Hypertens, 2020.
C. Broadhurst, Rhodes, A. M. L., Harper, P., Perry, D. C., Clarke, N. M. P., and Aarvold, A., “What is the incidence of late detection of developmental dysplasia of the hip in England?”, Bone Joint J, vol. 101-b, pp. 281-287, 2019.
V. M. Walker, Davies, N. M., Kehoe, P. G., and Martin, R. M., “What is the impact of regulatory guidance and expiry of drug patents on dementia drug prescriptions in England? A trend analysis in the Clinical Practice Research Datalink”, Alzheimers Res Ther, vol. 10, p. 51, 2018.
T. P. van Staa, Smeeth, L., Persson, I., Parkinson, J., and Leufkens, H. G., “What is the harm-benefit ratio of Cox-2 inhibitors?”, Int J Epidemiol, vol. 37, pp. 405-13, 2008.
G. E. Smith, Smith, S., Heatlie, H., Bashford, J. N., Hawker, J., Ashcroft, D., Millson, D., Verlander, N. Q., and Warren, R., “What has happened to antimicrobial usage in primary care in the United Kingdom since the SMAC report? - description of trends in antimicrobial usage using the General Practice Research Database”, J Public Health (Oxf), vol. 26, pp. 359-64, 2004.
D. Kernick, Stapley, S., Campbell, J., and Hamilton, W., “What happens to new-onset headache in children that present to primary care? A case-cohort study using electronic primary care records”, Cephalalgia, vol. 29, pp. 1311-6, 2009.
H. Strongman, Williams, R., and Bhaskaran, K., “What are the implications of using individual and combined sources of routinely collected data to identify and characterise incident site-specific cancers? a concordance and validation study using linked English electronic health records data”, BMJ Open, vol. 10, p. e037719, 2020.
N. M. Davies, Taylor, G., Taylor, A. E., Thomas, K. H., Windmeijer, F., Martin, R. M., and Munafo, M. R., “What are the effects of varenicline compared with nicotine replacement therapy on long-term smoking cessation and clinically important outcomes? Protocol for a prospective cohort study”, BMJ Open, vol. 5, p. e009665, 2015.
C. Santella, Yin, H., Hicks, B. M., Yu, O. H. Y., Bouganim, N., and Azoulay, L., “Weight-lowering effects of glucagon-like peptide-1 receptor agonists and detection of breast cancer among obese women with diabetes”, Epidemiology, 2020.
C. L. Morgan, Jenkins-Jones, S., Evans, M., Barnett, A. H., Poole, C. D., and Currie, C. J., “Weight change in people with type 2 diabetes: secular trends and the impact of alternative antihyperglycaemic drugs”, Diabetes Obes Metab, vol. 14, pp. 424-32, 2012.
B. T. Blak, Rigney, U., Sternhufvud, C., Davis, J., and Hammar, N., “Weight change and healthcare resource use in English patients with type 2 diabetes mellitus initiating a new diabetes medication class”, Int J Clin Pract, vol. 70, pp. 45-55, 2016.
A. M. Mueller, Meier, C. R., Jick, S. S., and Schneider, C., “Weight change and blood glucose concentration as markers for pancreatic cancer in subjects with new-onset diabetes mellitus: A matched case-control study”, Pancreatology, 2019.
L. Watson, Wilson, B. P., Alsop, J., and Kumar, S., “Weight and glycaemic control in type 2 diabetes: what is the outcome of insulin initiation?”, Diabetes Obes Metab, vol. 13, pp. 823-31, 2011.
C. Renoux, Dell'Aniello, S., Khairy, P., Marras, C., Bugden, S., Turin, T. C., Blais, L., Tamim, H., Evans, C., Steele, R., Dormuth, C., and Ernst, P., “Ventricular tachyarrhythmia and sudden cardiac death with domperidone use in Parkinson's disease”, Br J Clin Pharmacol, vol. 82, pp. 461-72, 2016.
A. A. Sultan, Muller, S., Whittle, R., Roddy, E., Mallen, C., and Clarson, L., “Venous thromboembolism in patients with gout and the impact of hospital admission, disease duration and urate-lowering therapy”, Cmaj, vol. 191, pp. E597-e603, 2019.
I. Little, Vinogradova, Y., Orton, E., Kai, J., and Qureshi, N., “Venous thromboembolism in adults screened for sickle cell trait: a population-based cohort study with nested case-control analysis”, BMJ Open, vol. 7, p. e012665, 2017.
H. E. Seaman, de Vries, C. S., and Farmer, R. D., “Venous thromboembolism associated with cyproterone acetate in combination with ethinyloestradiol (Dianette): observational studies using the UK General Practice Research Database”, Pharmacoepidemiol Drug Saf, vol. 13, pp. 427-36, 2004.
U. T. Khan, Walker, A. J., Baig, S., Card, T. R., Kirwan, C. C., and Grainge, M. J., “Venous thromboembolism and mortality in breast cancer: cohort study with systematic review and meta-analysis”, BMC Cancer, vol. 17, p. 747, 2017.
H. E. Seaman, Langley, S. E., Farmer, R. D., and de Vries, C. S., “Venous thromboembolism and cyproterone acetate in men with prostate cancer: a study using the General Practice Research Database”, BJU Int, vol. 99, pp. 1398-403, 2007.
R. Lawrenson and Farmer, R., “Venous thromboembolism and combined oral contraceptives: does the type of progestogen make a difference?”, Contraception, vol. 62, p. 21S-28S; discussion 37S-38S, 2000.
D. J. Margolis, Bilker, W., Santanna, J., and Baumgarten, M., “Venous leg ulcer: incidence and prevalence in the elderly”, J Am Acad Dermatol, vol. 46, pp. 381-6, 2002.
M. Ashworth, Charlton, J., Ballard, K., Latinovic, R., and Gulliford, M., “Variations in antibiotic prescribing and consultation rates for acute respiratory infection in UK general practices 1995-2000”, Br J Gen Pract, vol. 55, pp. 603-8, 2005.
A. J. Walker, West, J., Card, T. R., Humes, D. J., and Grainge, M. J., “Variation in the risk of venous thromboembolism in people with colorectal cancer: a population-based cohort study from England”, J Thromb Haemost, vol. 12, pp. 641-9, 2014.
D. J. Humes, Walker, A. J., Blackwell, J., Hunt, B. J., and West, J., “Variation in the risk of venous thromboembolism following colectomy”, Br J Surg, vol. 102, pp. 1629-38, 2015.
M. Giustozzi, Curcio, A., Weijs, B., Field, T. S., Sudikas, S., Katholing, A., Wallenhorst, C., Weitz, J. I., Martinez, C., and Cohen, A. T., “Variation in the Association between Antineoplastic Therapies and Venous Thromboembolism in Patients with Active Cancer”, Thromb Haemost, vol. 120, pp. 847-856, 2020.
A. Arana, Margulis, A. V., McQuay, L. J., Ziemiecki, R., Bartsch, J. L., Rothman, K. J., Franks, B., D'Silva, M., Appenteng, K., Varas-Lorenzo, C., and Perez-Gutthann, S., “Variation in Cardiovascular Risk Related to Individual Antimuscarinic Drugs Used to Treat Overactive Bladder: A UK Cohort Study”, Pharmacotherapy, vol. 38, pp. 628-637, 2018.
R. Boggon, Hubbard, R., Smeeth, L., Gulliford, M., Cassell, J., Eaton, S., Pirmohamed, M., and van Staa, T. P., “Variability of antibiotic prescribing in patients with chronic obstructive pulmonary disease exacerbations: a cohort study”, BMC Pulm Med, vol. 13, p. 32, 2013.
D. Henry, Lim, L. L., Rodriguez, L. A. Garcia, S. Gutthann, P., Carson, J. L., Griffin, M., Savage, R., Logan, R., Moride, Y., Hawkey, C., Hill, S., and Fries, J. T., “Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis”, Bmj, vol. 312, pp. 1563-6, 1996.
J. A. Critchley, Carey, I. M., Harris, T., DeWilde, S., and Cook, D. G., “Variability in Glycated Hemoglobin and Risk of Poor Outcomes Among People With Type 2 Diabetes in a Large Primary Care Cohort Study”, Diabetes Care, vol. 42, pp. 2237-2246, 2019.
N. M. Davies, Taylor, A. E., Taylor, G. M., Itani, T., Jones, T., Martin, R. M., Munafo, M. R., Windmeijer, F., and Thomas, K. H., “Varenicline versus nicotine replacement therapy for long-term smoking cessation: an observational study using the Clinical Practice Research Datalink”, Health Technol Assess, vol. 24, pp. 1-46, 2020.
D. Gunnell, Irvine, D., Wise, L., Davies, C., and Martin, R. M., “Varenicline and suicidal behaviour: a cohort study based on data from the General Practice Research Database”, Bmj, vol. 339, p. b3805, 2009.
R. D. Mann, “The VAMP system and the detection of risk, some examples”, Pharmacoepidemiology and Drug Safety, vol. 3, pp. 313-319, 1994.
A. V. Margulis, Fortuny, J., Kaye, J. A., Calingaert, B., Reynolds, M., Plana, E., McQuay, L. J., Atsma, W. J., Franks, B., de Vogel, S., Perez-Gutthann, S., and Arana, A., “Value of Free-text Comments for Validating Cancer Cases Using Primary-care Data in the United Kingdom”, Epidemiology, vol. 29, pp. e41-e42, 2018.
S. F. Weng, Kai, J., Guha, I. N., and Qureshi, N., “The value of aspartate aminotransferase and alanine aminotransferase in cardiovascular disease risk assessment”, Open Heart, vol. 2, p. e000272, 2015.
S. S. Jick, Kaye, J. A., Vasilakis-Scaramozza, C., Rodriguez, L. A. Garcia, Ruigomez, A., Meier, C. R., Schlienger, R. G., Black, C., and Jick, H., “Validity of the general practice research database”, Pharmacotherapy, vol. 23, pp. 686-9, 2003.
[Page last reviewed 4 March 2021]